Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era?
作者信息
Svensson Di Giorgio Sofia, Yoshino Jun, Morandi Alessio, Scandavini Chiara Maria, Halimi Asif, Coppola Alessandro, Valente Roberto
机构信息
Department of Diagnostics and Interventions, Surgery, Umeå University, Umeå, Sweden.
Department of Surgery, Sapienza University of Rome, Rome, Italy.
出版信息
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1054-1057. doi: 10.21037/hbsn-24-603. Epub 2024 Nov 21.
Abstract
摘要
相似文献
1
Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era?伴有肝转移的胰腺导管腺癌的手术切除：这是一个新时代的开端吗？
Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1054-1057. doi: 10.21037/hbsn-24-603. Epub 2024 Nov 21.
2
Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.伴有同步肝转移的胰腺导管腺癌的术前评估：不可切除性的诊断与评估
World J Gastroenterol. 2016 Dec 7;22(45):10024-10037. doi: 10.3748/wjg.v22.i45.10024.
3
Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma.转录组分析揭示胰腺导管腺癌中与肝转移相关的基因。
Math Biosci Eng. 2021 Feb 5;18(2):1708-1721. doi: 10.3934/mbe.2021088.
4
Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.胰导管腺癌患者根治性切除术后早期复发的危险因素。
World J Surg Oncol. 2023 Aug 24;21(1):263. doi: 10.1186/s12957-023-03141-3.
5
Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma.胰腺导管腺癌切除术后肝转移分析。
World J Gastrointest Oncol. 2012 May 15;4(5):109-14. doi: 10.4251/wjgo.v4.i5.109.
6
Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report.胰管腺癌异时性肝转移肝切除术后的长期生存：一例报告
Surg Case Rep. 2020 Jul 3;6(1):157. doi: 10.1186/s40792-020-00924-8.
7
Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?手术切除转移性病灶对孤立性肺转移的胰腺导管腺癌患者有益吗？
Cancers (Basel). 2022 Apr 20;14(9):2067. doi: 10.3390/cancers14092067.
8
MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.MUC16 通过上调 NRP2 相关细胞黏附促进胰腺导管腺癌肝转移。
Mol Cancer Res. 2022 Aug 5;20(8):1208-1221. doi: 10.1158/1541-7786.MCR-21-0888.
9
The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).基质肿瘤浸润淋巴细胞在胰腺导管腺癌（PDAC）中的预测价值和作用。
Cancer Biol Ther. 2018 Apr 3;19(4):296-305. doi: 10.1080/15384047.2017.1416932. Epub 2018 Feb 22.
10
Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.单细胞转录组分析揭示了胰腺腺癌肝转移的亚克隆进化和微环境变化及其临床意义。
Mol Cancer. 2024 May 3;23(1):87. doi: 10.1186/s12943-024-02003-0.
本文引用的文献
1
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.NALIRIFOX、FOLFIRINOX 和吉西他滨联合 Nab-紫杉醇作为转移性胰腺癌一线化疗：系统评价和荟萃分析。
JAMA Netw Open. 2024 Jan 2;7(1):e2350756. doi: 10.1001/jamanetworkopen.2023.50756.
2
An invited commentary on 'Preoperative CA19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: A further plea for biological resectability criteria'.一篇关于《术前CA19.9水平预测可切除性胰头腺癌的淋巴结转移：对生物学可切除性标准的进一步呼吁》的特邀评论。
Int J Surg. 2024 Oct 1;110(10):6456-6457. doi: 10.1097/JS9.0000000000001001.
3
Natural History of Stage IV Pancreatic Cancer. Identifying Survival Benchmarks for Curative-intent Resection in Patients With Synchronous Liver-only Metastases.IV 期胰腺癌的自然病程。同步肝转移患者行治愈性切除术的生存基准的确定。
Ann Surg. 2023 Oct 1;278(4):e798-e804. doi: 10.1097/SLA.0000000000005753. Epub 2022 Nov 10.
4
Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives.CA 19.9在可切除胰腺癌管理中的作用：现状与未来展望
Biomedicines. 2022 Aug 26;10(9):2091. doi: 10.3390/biomedicines10092091.
5
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver.胰腺癌肝转移行胰切除术的预后因素。
Ann Surg Oncol. 2022 Dec;29(13):8503-8510. doi: 10.1245/s10434-022-12385-4. Epub 2022 Aug 17.
6
Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis.胰腺导管腺癌伴肝转移行切除手术的生存获益：一项倾向评分匹配的监测、流行病学与结果（SEER）数据库分析
Cancers (Basel). 2021 Dec 23;14(1):57. doi: 10.3390/cancers14010057.
7
Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology.选择局部进展期胰腺癌的手术候选者：现代胰腺病学综述
J Gastrointest Oncol. 2021 Oct;12(5):2475-2483. doi: 10.21037/jgo-21-119.
8
Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review.胰腺癌同步和异时性单器官转移的手术治疗：SEER 数据库分析和系统文献回顾。
Sci Rep. 2020 Mar 10;10(1):4444. doi: 10.1038/s41598-020-61487-0.
9
Oligometastases in pancreatic cancer (Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis).胰腺癌中的寡转移（肝寡转移胰腺癌的同期切除术：在回顾性多中心分析中对安全胰腺手术时代的一项原则提出质疑）
Ann Gastroenterol Surg. 2019 Apr 29;3(4):373-377. doi: 10.1002/ags3.12255. eCollection 2019 Jul.
10
Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature.转移性胰腺导管腺癌的外科治疗：对当前文献的综述。
Pancreatology. 2019 Jul;19(5):672-680. doi: 10.1016/j.pan.2019.05.466. Epub 2019 Jun 7.
Zotero 插件